PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aquestive Therapeutics, Inc. (AQST)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS03843E1047
CUSIP03843E104
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$394.06M
EPS-$0.13
Revenue (TTM)$50.58M
Gross Profit (TTM)$28.29M
EBITDA (TTM)-$13.73M
Year Range$0.82 - $6.23
Target Price$9.17
Short %3.38%
Short Ratio1.34

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AQST

Aquestive Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aquestive Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%OctoberNovemberDecember2024FebruaryMarch
-74.45%
84.41%
AQST (Aquestive Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aquestive Therapeutics, Inc. had a return of 102.97% year-to-date (YTD) and 357.49% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date102.97%10.04%
1 month43.86%3.53%
6 months169.74%22.79%
1 year357.49%32.16%
5 years (annualized)-9.94%13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202418.32%53.56%
2023-25.11%-6.71%2.61%43.31%-10.22%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Aquestive Therapeutics, Inc. (AQST) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AQST
Aquestive Therapeutics, Inc.
4.13
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Aquestive Therapeutics, Inc. Sharpe ratio is 4.13. A Sharpe ratio of 3.0 or higher is considered excellent.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00OctoberNovemberDecember2024FebruaryMarch
4.13
2.76
AQST (Aquestive Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aquestive Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-78.38%
0
AQST (Aquestive Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aquestive Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aquestive Therapeutics, Inc. was 96.68%, occurring on Jul 1, 2022. The portfolio has not yet recovered.

The current Aquestive Therapeutics, Inc. drawdown is 78.38%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.68%Sep 10, 2018960Jul 1, 2022
-6.54%Jul 26, 20188Aug 6, 20185Aug 13, 201813
-6.17%Aug 15, 20189Aug 27, 20182Aug 29, 201811
-0.67%Sep 4, 20181Sep 4, 20182Sep 6, 20183

Volatility

Volatility Chart

The current Aquestive Therapeutics, Inc. volatility is 43.37%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%OctoberNovemberDecember2024FebruaryMarch
43.37%
2.82%
AQST (Aquestive Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aquestive Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items